SCHEMBL394467

SCHEMBL394467

FC(F)(F)c1cc(Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc(C(F)(F)F)c1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAPGEF4 Q8WZA2 2/20 0.59
AKR1C3 P42330 2/20 0.53
AKR1C2 P52895 2/20 0.53
MAPT P10636 1/20 0.48
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
PIK3CG P48736 1/20 0.46
XPO1 O14980 1/20 0.45
GPR35 Q9HC97 1/20 0.45
IDO1 P14902 2/20 0.44
CES2 O00748 1/20 0.44
P2RX1 P51575 3/20 0.44
LMNA P02545 1/20 0.44
KIF11 P52732 1/20 0.42
ACP1 P24666 1/20 0.42
GRM4 Q14833 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23059923 0.88 AKR1C3 (0.50) RAPGEF4AKR1C3AKR1C2PIK3CGP2RX1
SCHEMBL16481381 0.86 AKR1C3 (0.62) RAPGEF4AKR1C3AKR1C2MAPTPIK3CG
SCHEMBL16481311 0.84 APP (0.49) RAPGEF4AKR1C3AKR1C2MAPTPIK3CG
SCHEMBL8795017 0.82 MAPT (0.48) RAPGEF4AKR1C3AKR1C2MAPTXPO1
SCHEMBL23933954 0.81 RAPGEF4 (0.58) RAPGEF4AKR1C3AKR1C2MAPTHDAC3
SCHEMBL440959 0.80 CES2 (0.58) RAPGEF4MAPTXPO1GPR35IDO1
SCHEMBL22542884 0.79 GRM4 (0.53) RAPGEF4AKR1C3AKR1C2MAPTHDAC3
SCHEMBL16344857 0.78 MAPT (0.65) RAPGEF4AKR1C3AKR1C2MAPTPIK3CG
SCHEMBL9218591 0.78 ALDH1A1 (0.53) RAPGEF4AKR1C3AKR1C2MAPTHDAC3
SCHEMBL10700885 0.78 AKR1C3 (0.43) RAPGEF4AKR1C3AKR1C2MAPTPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577373-B2 Carbodiimide composition, curing agent composition, coating composition and resin cured product ASAHI KASEI KABUSHIKI KAISHA (JP) 2026-03-17 US disclosed
US-20230135772-A1 CARBODIIMIDE COMPOSITION, CURING AGENT COMPOSITION, COATING COMPOSITION AND RESIN CURED PRODUCT ASAHI KASEI KABUSHIKI KAISHA (JP) 2023-05-04 US disclosed
CN-111362986-B Thieno [2,3-d ] pyridazine cyclometalated iridium complex and preparation method thereof 安徽工业大学 2023-04-07 CN disclosed
EP-4130154-A1 CARBODIIMIDE COMPOSITION, HARDENER COMPOSITION, COATING COMPOSITION, AND CURED RESIN OBJECT Asahi Kasei Kabushiki Kaisha (JP) 2023-02-08 EP disclosed
CN-109641899-B Compounds and compositions as endosomal Toll-like receptor inhibitors 诺华股份有限公司 2022-07-22 CN disclosed
WO-2021036683-A1 AROMATIC AMINE COMPOUND, COATING LAYER MATERIAL AND LIGHT EMITTING ELEMENT 东丽先端材料研究开发(中国)有限公司 2021-03-04 WO disclosed
US-9695260-B2 Method for producing olefin block polymer using plurality of types of transition metal catalysts SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-07-04 US disclosed
US-9593194-B2 Method for producing olefin block polymer using group 4 transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-03-14 US disclosed
US-9200093-B2 Polymerization method using surfactant-containing particle SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-12-01 US disclosed
US-8871885-B2 Ethylene-a-olefin copolymer and molded article SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-10-28 US disclosed
US-20020143124-A1 Homogeneous type solid catalyst component or homogeneous type solid catalyst, process for production thereof and process for producing addition polymer with the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-10-03 US disclosed
US-6335303-B1 EFFECTIVE IN POLYMERIZATION OF ALPHA OLEFINS TO HIGH MOLECULAR WEIGHT POLYMERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2002-01-01 US disclosed
EP-1153938-A1 CATALYST FOR STEREOREGULAR POLYMERIZATION OF ALPHA-OLEFIN AND PROCESS FOR PRODUCING STEREOREGULAR ALPHA-OLEFIN POLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-11-14 EP disclosed
US-20010020075-A1 Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-09-06 US disclosed
US-6284699-B1 COORDINATION POLYMERIZATION CATALYSTS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-09-04 US disclosed
EP-1114832-A1 Modified particles, catalyst for olefin polymerization using the same, and process of producing olefin polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-07-11 EP disclosed
US-20010007007-A1 Modified particles, catalyst for olefin polymerization using the same, and process of producing olefin polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-07-05 US disclosed
EP-1113026-A2 Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-07-04 EP disclosed
EP-0949273-A1 MODIFIED PARTICLES, CARRIER PREPARED THEREFROM, OLEFIN POLYMERIZATION CATALYST COMPONENT PREPARED THEREFROM, OLEFIN POLYMERIZATION CATALYST PREPARED THEREFROM, AND PROCESS FOR PREPARING OLEFIN POLYMER Sumitomo Chemical Company, Limited (JP) 1999-10-13 EP disclosed
WO-1998045039-A1 POLYMERIZATION CATALYSTS CONTAINING ELECTRON-WITHDRAWING AMIDE LIGANDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577373-B2 Carbodiimide composition, curing agent composition, coating composition and resin cured product CD38, PARP9, MCCC2 RAPGEF4 2821/4885AKR1C3 1711/4885AKR1C2 1990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.